REGN - Alnylam says kidney disease therapy led to 37% drop in key indicator

Alnylam Pharmaceuticals (NASDAQ:ALNY), a biotech focused on RNA interference, announced Thursday that its experimental RNAi therapy cemdisiran caused a 37% mean reduction of an important indicator of disease progression in immunoglobulin A nephropathy ((IgAN)). Alnylam (ALNY) has partnered with Regeneron (REGN) to develop cemdisiran for IgAN, an inflammatory condition affecting the kidney, often leading to kidney failure. Sharing topline results from a 31-patient Phase 2 trial, Alnylam (ALNY) said that at week 32, cemdisiran resulted in a 37% mean reduction of the 24-hour urine protein to creatinine ratio relative to placebo, the primary endpoint of the trial, and a key indicator of the disease progression. While the results of secondary endpoints were consistent with the treatment benefit of cemdisiran, 12 of 22 (55%) patients in the cemdisiran group experienced treatment-emergent AEs whch were related to the study drug, the company said. In comparison, only two of nine (22%) patients on

For further details see:

Alnylam says kidney disease therapy led to 37% drop in key indicator